302 related articles for article (PubMed ID: 32339229)
1. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study.
Conley BA; Staudt L; Takebe N; Wheeler DA; Wang L; Cardenas MF; Korchina V; Zenklusen JC; McShane LM; Tricoli JV; Williams PM; Lubensky I; O'Sullivan-Coyne G; Kohn E; Little RF; White J; Malik S; Harris LN; Mann B; Weil C; Tarnuzzer R; Karlovich C; Rodgers B; Shankar L; Jacobs PM; Nolan T; Berryman SM; Gastier-Foster J; Bowen J; Leraas K; Shen H; Laird PW; Esteller M; Miller V; Johnson A; Edmondson EF; Giordano TJ; Kim B; Ivy SP
J Natl Cancer Inst; 2021 Jan; 113(1):27-37. PubMed ID: 32339229
[TBL] [Abstract][Full Text] [Related]
2. Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine.
Tsimberidou AM; Said R; Staudt LM; Conley BA; Takebe N
Cancer J; 2019; 25(4):296-299. PubMed ID: 31335394
[TBL] [Abstract][Full Text] [Related]
3. Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers.
Khater F; Vairy S; Langlois S; Dumoucel S; Sontag T; St-Onge P; Bittencourt H; Dal Soglio D; Champagne J; Duval M; Leclerc JM; Laverdiere C; Tran TH; Patey N; Ellezam B; Perreault S; Piché N; Samson Y; Teira P; Jabado N; Michon B; Brossard J; Marzouki M; Cellot S; Sinnett D
JAMA Netw Open; 2019 Apr; 2(4):e192906. PubMed ID: 31026031
[TBL] [Abstract][Full Text] [Related]
4. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
5. Molecular Profiling of Exceptional Responders to Cancer Therapy.
Bilusic M; Girardi D; Zhou Y; Jung K; Pei J; Slifker M; Chen Q; Meerzaman D; Alpaugh K; Young D; Flieder D; Gray P; Plimack E
Oncologist; 2021 Mar; 26(3):186-195. PubMed ID: 33210795
[TBL] [Abstract][Full Text] [Related]
6. Integrated next-generation sequencing and avatar mouse models for personalized cancer treatment.
Garralda E; Paz K; López-Casas PP; Jones S; Katz A; Kann LM; López-Rios F; Sarno F; Al-Shahrour F; Vasquez D; Bruckheimer E; Angiuoli SV; Calles A; Diaz LA; Velculescu VE; Valencia A; Sidransky D; Hidalgo M
Clin Cancer Res; 2014 May; 20(9):2476-84. PubMed ID: 24634382
[TBL] [Abstract][Full Text] [Related]
7. Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting.
Lee B; Tran B; Hsu AL; Taylor GR; Fox SB; Fellowes A; Marquis R; Mooi J; Desai J; Doig K; Ekert P; Gaff C; Herath D; Hamilton A; James P; Roberts A; Snyder R; Waring P; McArthur G
Intern Med J; 2018 Jul; 48(7):786-794. PubMed ID: 29607586
[TBL] [Abstract][Full Text] [Related]
8. Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Tuxen IV; Rohrberg KS; Oestrup O; Ahlborn LB; Schmidt AY; Spanggaard I; Hasselby JP; Santoni-Rugiu E; Yde CW; Mau-Sørensen M; Nielsen FC; Lassen U
Clin Cancer Res; 2019 Feb; 25(4):1239-1247. PubMed ID: 30274980
[TBL] [Abstract][Full Text] [Related]
9. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.
Wheler J; Yelensky R; Falchook G; Kim KB; Hwu P; Tsimberidou AM; Stephens PJ; Hong D; Cronin MT; Kurzrock R
BMC Cancer; 2015 Feb; 15():61. PubMed ID: 25886620
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system.
Hayashi H; Tanishima S; Fujii K; Mori R; Okada C; Yanagita E; Shibata Y; Matsuoka R; Amano T; Yamada T; Yabe I; Kinoshita I; Komatsu Y; Dosaka-Akita H; Nishihara H
Cancer Sci; 2020 Oct; 111(10):3926-3937. PubMed ID: 32772458
[TBL] [Abstract][Full Text] [Related]
11. Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Park HS; Lim SM; Kim S; Kim S; Kim HR; Kwack K; Lee MG; Kim JH; Moon YW
PLoS One; 2016; 11(4):e0154133. PubMed ID: 27105424
[TBL] [Abstract][Full Text] [Related]
12. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial.
Bertucci F; Gonçalves A; Guille A; Adelaïde J; Garnier S; Carbuccia N; Billon E; Finetti P; Sfumato P; Monneur A; Pécheux C; Khran M; Brunelle S; Mescam L; Thomassin-Piana J; Poizat F; Charafe-Jauffret E; Turrini O; Lambaudie E; Provansal M; Extra JM; Madroszyk A; Gilabert M; Sabatier R; Vicier C; Mamessier E; Chabannon C; Pakradouni J; Viens P; André F; Gravis G; Popovici C; Birnbaum D; Chaffanet M
Genome Med; 2021 May; 13(1):87. PubMed ID: 34006291
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors.
Cobain EF; Wu YM; Vats P; Chugh R; Worden F; Smith DC; Schuetze SM; Zalupski MM; Sahai V; Alva A; Schott AF; Caram MEV; Hayes DF; Stoffel EM; Jacobs MF; Kumar-Sinha C; Cao X; Wang R; Lucas D; Ning Y; Rabban E; Bell J; Camelo-Piragua S; Udager AM; Cieslik M; Lonigro RJ; Kunju LP; Robinson DR; Talpaz M; Chinnaiyan AM
JAMA Oncol; 2021 Apr; 7(4):525-533. PubMed ID: 33630025
[TBL] [Abstract][Full Text] [Related]
14. Quantitation of Targetable Somatic Mutations Among Patients Evaluated by a Personalized Medicine Clinical Service: Considerations for Off-Label Drug Use.
Vela CM; Knepper TC; Gillis NK; Walko CM; McLeod HL; Hicks JK
Pharmacotherapy; 2017 Sep; 37(9):1043-1051. PubMed ID: 28235141
[TBL] [Abstract][Full Text] [Related]
15. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
16. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
17. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH).
Flaherty KT; Gray RJ; Chen AP; Li S; McShane LM; Patton D; Hamilton SR; Williams PM; Iafrate AJ; Sklar J; Mitchell EP; Harris LN; Takebe N; Sims DJ; Coffey B; Fu T; Routbort M; Zwiebel JA; Rubinstein LV; Little RF; Arteaga CL; Comis R; Abrams JS; O'Dwyer PJ; Conley BA;
J Clin Oncol; 2020 Nov; 38(33):3883-3894. PubMed ID: 33048619
[TBL] [Abstract][Full Text] [Related]
18. Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.
Tran B; Brown AM; Bedard PL; Winquist E; Goss GD; Hotte SJ; Welch SA; Hirte HW; Zhang T; Stein LD; Ferretti V; Watt S; Jiao W; Ng K; Ghai S; Shaw P; Petrocelli T; Hudson TJ; Neel BG; Onetto N; Siu LL; McPherson JD; Kamel-Reid S; Dancey JE
Int J Cancer; 2013 Apr; 132(7):1547-55. PubMed ID: 22948899
[TBL] [Abstract][Full Text] [Related]
19. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation-the NCT Neuro Master Match (N2M2) pilot study.
Pfaff E; Kessler T; Balasubramanian GP; Berberich A; Schrimpf D; Wick A; Debus J; Unterberg A; Bendszus M; Herold-Mende C; Capper D; Schenkel I; Eisenmenger A; Dettmer S; Brors B; Platten M; Pfister SM; von Deimling A; Jones DTW; Wick W; Sahm F
Neuro Oncol; 2018 May; 20(6):826-837. PubMed ID: 29165638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
